Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Conduritol B Epoxide SCHEMBL14973473 | 1.00 | GBA1 (1.00) | GBA1LMNAAPPALDH1A1TSHR | |
| Conduritol B Epoxide SCHEMBL29386033 | 1.00 | GBA1 (1.00) | GBA1LMNAAPPALDH1A1TSHR | |
| SCHEMBL6433027 | 1.00 | — | — | |
| Conduritol B Epoxide SCHEMBL16204471 | 1.00 | GBA1 (1.00) | GBA1LMNAAPPALDH1A1TSHR | |
| SCHEMBL18390184 | 0.95 | GBA1 (0.91) | GBA1LMNAAPPALDH1A1TSHR | |
| SCHEMBL6790705 | 0.86 | GBA1 (0.75) | GBA1LMNAAPPALDH1A1TSHR | |
| SCHEMBL6790708 | 0.86 | GBA1 (0.75) | GBA1LMNAAPPALDH1A1TSHR | |
| SCHEMBL12346253 | 0.80 | GBA1 (0.65) | GBA1 | |
| Cyclophellitol SCHEMBL21778094 | 0.76 | GBA1 (0.58) | GBA1LMNAALDH1A1TSHRTDP1 | |
| Cyclophellitol SCHEMBL12232222 | 0.76 | GBA1 (0.58) | GBA1LMNAALDH1A1TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114479735-A | Cationic UV curing adhesive and preparation method and application thereof | 张河远 | 2022-05-13 | — | — | CN | claimed |
| US-20260027213-A1 | EPICARDIAL-DERIVED PARACRINE FACTORS FOR REPAIRING CARDIAC TISSUE | REGENCOR INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12458689-B2 | Escherichia coli compositions and methods thereof | PFIZER INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20250205306-A1 | USE OF FOLLISTATIN-LIKE 1 (FSTL1) IN CARDIOMETABOLIC HEART FAILURE | REGENCOR, INC. | 2025-06-26 | — | — | US | disclosed |
| US-20250114442-A1 | ESCHERICHIA COLI COMPOSITIONS AND METHODS THEREOF | PFIZER (US) | 2025-04-10 | — | — | US | disclosed |
| EP-4499125-A1 | USE OF FOLLISTATIN-LIKE 1 (FSTL1) IN CARDIOMETABOLIC HEART FAILURE | Regencor, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| US-12138302-B2 | Escherichia coli compositions and methods thereof | PFIZER INC. (US) | 2024-11-12 | — | — | US | disclosed |
| US-20240325513-A1 | ESCHERICHIA COLI COMPOSITIONS AND METHODS THEREOF | PFIZER (US) | 2024-10-03 | — | — | US | disclosed |
| WO-2023183933-A1 | USE OF FOLLISTATIN-LIKE 1 (FSTL1) IN CARDIOMETABOLIC HEART FAILURE | REGENCOR, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| EP-4237428-A2 | ESCHERICHIA COLI COMPOSITIONS AND METHODS THEREOF | Pfizer Inc. (US) | 2023-09-06 | — | — | EP | disclosed |
| US-8007814-B2 | Therapy for lysosomal enzyme deficiencies | UNIVERSITY OF MASSACHUSETTS (US) | 2011-08-30 | — | — | US | disclosed |
| US-20110028719-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | WARATAH PHARMACEUTICALS INC. (CA) | 2011-02-03 | — | — | US | disclosed |
| US-20110028719-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | WARATAH PHARMACEUTICALS INC. (CA) | 2011-02-03 | — | — | US | disclosed |
| EP-1802289-A2 | COMPOSITIONS AND THEIR USES FOR LYSOSOMAL ENZYME DEFICIENCIES | University of Massachusetts (US) | 2007-07-04 | — | — | EP | disclosed |
| US-20060083718-A1 | Novel therapy for lysosomal enzyme deficiencies | UNIVERSITY OF MASSACHUSETTS (US) | 2006-04-20 | — | — | US | disclosed |
| WO-2006032039-A2 | COMPOSITIONS AND THEIR USES FOR LYSOSOMAL ENZYME DEFICIENCIES | UNIVERSITY OF MASSACHUSETTS (US) | 2006-03-23 | — | — | WO | disclosed |
| EP-1172400-B1 | THERMOPLASTIC RESIN FILM WITH SATISFACTORY PRINTABILITY | YUPO CORP (JP) | 2005-12-28 | — | — | EP | disclosed |
| US-6586106-B2 | Ink transfer, adhesion and aging stability, and being satisfactory in back ghost when offset printing using oxidation polymerization type ink is performed on both faces | YUPO CORPORATION (JP) | 2003-07-01 | — | — | US | disclosed |
| US-20020054991-A1 | Thermoplastic resin film satisfactory in printability | YUPO CORPORATION (JP) | 2002-05-09 | — | — | US | disclosed |
| EP-1172400-A1 | THERMOPLASTIC RESIN FILM WITH SATISFACTORY PRINTABILITY | Yupo Corporation (JP) | 2002-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12458689-B2 | Escherichia coli compositions and methods thereof | MRPL21, DDOST, OSTC | GBA1 2642/4885LMNA 1242/4885APP 541/4885 |
| US-20110028719-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | APP, BACE1, IAPP | GBA1 163/4885LMNA 1372/4885APP 1/4885 |
| US-20240325513-A1 | ESCHERICHIA COLI COMPOSITIONS AND METHODS THEREOF | MRPL21, DDOST, OSTC | GBA1 2642/4885LMNA 1242/4885APP 541/4885 |
| US-20260027213-A1 | EPICARDIAL-DERIVED PARACRINE FACTORS FOR REPAIRING CARDIAC TISSUE | TNNI3, TNNT2, FN1 | GBA1 3902/4885LMNA 1602/4885APP 1966/4885 |
| US-20250114442-A1 | ESCHERICHIA COLI COMPOSITIONS AND METHODS THEREOF | MRPL21, DDOST, STT3A | GBA1 2473/4885LMNA 1348/4885APP 1385/4885 |
| US-12138302-B2 | Escherichia coli compositions and methods thereof | MRPL21, DDOST, STT3A | GBA1 2473/4885LMNA 1348/4885APP 1385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.